NHS England now offers the "Trojan horse" therapy, belantamab mafodotin (Blenrep) for patients with multiple myeloma.

GSK's regulatory filing for expanded use of RSV vaccine, Arexvy, in adults aged 18 years and older has been accepted for ...

This FTSE 100 pharmaceutical giant has been hit by fears of US tariffs and litigation over a key product, but this could mean ...

GSK has licensed altSonflex1-2-3, its Shigella vaccine candidate, to Bharat Biotech for the continued development and ...

GSK has applied to the European Medicines Agency to expand use of its respiratory syncytial virus (RSV) vaccine to adults ...

GSK PLC closed 11.51% short of its 52-week high of £16.79, which the company achieved on September 9th.

GSK’s Blenrep (belantamab mafodotin) has been recommended by the National Institute for Health and Care Excellence (NICE) as ...

Arexvy is already approved in the European Economic Area for the prevention of lower respiratory tract disease (LRTD) caused ...

Drugmaker GSK said on Friday that its RSV vaccine, Arexvy, has been accepted for regulatory review by the European Medicines ...

England is the first country in the world to make GSK's anti-BCMA drug Blenrep available to patients with the haematological ...

The trial evaluated the combination of GSK’s Jemperli and Zejula as a first-line therapy for stage III and IV epithelial OC.

In a world grappling with urgent health threats, these youth advocates are offering bold solutions and renewed hope for the future.